Lung Cancer

 

Tips&Tools

About
 Daily News from Top Searches
Popular Searches
Tips on Searching
SearchMedica for IPhone
Go To SearchMedica
Sign Up For Our Newsletter


LungCancerNews

ORIGINAL CONTRIBUTION Computed Tomography Screening and Lung Cancer Outcomes Peter B. Bach, MD, MAPP James R. Jett, MD Ugo Pastorino, MD Melvyn S. Tockman, MD, PhD Stephen J. Swensen, MD, MMM Colin B. Begg, PhD LUNG CAN
www.medpagetoday.com -
www.medpagetoday.com/upload/2008/10/3/871.pdf
www.medpagetoday.com -
www.medpagetoday.com/upload/2010/1/22/b5569.pdf
www.medpagetoday.com -
www.medpagetoday.com/upload/2010/11/11/mm5944.pdf
www.medpagetoday.com -
Medical News: Lung Cancer Drug Trial Halted for Lack of Efficacy
www.medpagetoday.com -
Interim results from a phase III trial of vadimezan ( ASA404) in non-small cell lung cancer indicated no survival benefit, forcing an end to the study. ... The planned interim analysis of data from the ATTRACT-1 phase III trial of ASA404 in previously

Result Pages: 1 2 3 4 5 6 7 Next



FeaturedArticles

February 9, 2012
New Testing for Lung Cancer Screening
In this review, the authors discuss past attempts at lung cancer screening, the results of the National Lung Cancer Screening Trial, and innovative tests for lung cancer screening currently being evaluated. More »
February 9, 2012
Formidable Challenges Ahead for Lung Cancer Screening
Tanner et al provide a concise review of lung cancer screening, including discussion of past failed attempts, the success of the National Lung Screening Trial (NLST), and promising new avenues for improving on the NLST results. More »
November 4, 2011
Non-Small-Cell Lung Cancer
Lung cancer has been the leading cause of cancer death among men in the United States for years, and since 1988, it has become the number-one cause of cancer death among women. More »
November 1, 2011
Small-Cell Lung Cancer, Mesothelioma, and Thymoma
There are two major subdivisions of lung cancer: small-cell lung cancer (SCLC), for which chemotherapy is the primary treatment, and non-small-cell lung cancer (NSCLC). More »
July 6, 2011
COX-2 Inhibitor, Celecoxib, May Prevent Lung Cancer
A study in the AACR journal Cancer Prevention Research, has shown evidence that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, may be a potent chemopreventive agent for lung cancer. More »
Showing 1 - 5 of 115 results.
Page of 23
First Previous Last

ResearchandReviews

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
pubmed.gov - 5/15/12
Arch Neurol
archneur.ama-assn.org - 5/7/12
PLoS ONE: EGFR-Mediated Carcinoma Cell Metastasis Mediated by Integrin v5 Depends on Activation of c-Src and Cleavage of MUC1
www.plosone.org - 5/7/12
Xeroderma pigmentosum
ghr.nlm.nih.gov - 5/7/12
Search Results
ghr.nlm.nih.gov - 5/7/12
More Results

ArticlesandNews

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
pubmed.gov - 5/15/12
Arch Neurol
archneur.ama-assn.org - 5/7/12
PLoS ONE: EGFR-Mediated Carcinoma Cell Metastasis Mediated by Integrin v5 Depends on Activation of c-Src and Cleavage of MUC1
www.plosone.org - 5/7/12
Xeroderma pigmentosum
ghr.nlm.nih.gov - 5/7/12
Search Results
ghr.nlm.nih.gov - 5/7/12
More Results

PubMed

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
pubmed.gov - 5/15/12
Arch Neurol
archneur.ama-assn.org - 5/7/12
PLoS ONE: EGFR-Mediated Carcinoma Cell Metastasis Mediated by Integrin v5 Depends on Activation of c-Src and Cleavage of MUC1
www.plosone.org - 5/7/12
Xeroderma pigmentosum
ghr.nlm.nih.gov - 5/7/12
Search Results
ghr.nlm.nih.gov - 5/7/12
ALK
ghr.nlm.nih.gov - 5/7/12
More Results

ClinicalTrials

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
pubmed.gov - 5/15/12
Arch Neurol
archneur.ama-assn.org - 5/7/12
PLoS ONE: EGFR-Mediated Carcinoma Cell Metastasis Mediated by Integrin v5 Depends on Activation of c-Src and Cleavage of MUC1
www.plosone.org - 5/7/12
Xeroderma pigmentosum
ghr.nlm.nih.gov - 5/7/12
Search Results
ghr.nlm.nih.gov - 5/7/12
ALK
ghr.nlm.nih.gov - 5/7/12
More Results


TopicIndex

PracticeGuidelines

Guide to Clinical Preventive Services, 2010-2011: Section 2
www.ahrq.gov - 9/1/10
Lung Cancer Guidelines
www.brit-thoracic.org.uk -
Table 3 Sample Size Requirements for Randomized Controlled Trials of Lung Cancer Screening
www.acponline.org -
Figure 4. Age-specific mortality rates for lung cancer. Predicted rates (dotted line) are reasonably close to those observed by the Surveillance, Epidemiology, and End Results program (solid line).
www.acponline.org -
More Results


FromPhysiciansPractice

Physician Performance Goals Are Great, But Balance Is More Realistic
Jennifer Frank, MD,  May 15, 2012
Performance measurements for physicians are well-intentioned and get me to rethink how I practice. But in the end I won't make the goals, so I'll have to go with balance over perfection.
Designing the Perfect Business Card for Your Medical Practice
C. Noel Henley, MD,  May 11, 2012
Does your business card say anything substantive about the valuable work you do in your practice? Here’s how to re-design your next business card for maximum impact and engagement.
Registered Nurses an Ideal Fit for Primary Care Practices
Audrey "Christie" McLaughlin, RN,  May 10, 2012
Here are four good reasons to hire a registered nurse for your primary care practice …maybe even instead of a medical assistant.
The Five Biggest Medical Practice Marketing Mistakes
James Doulgeris,  May 10, 2012
There are best practices to marketing your practice, but often, success is more about knowing what not to do. Here are the five most common pitfalls …and how to avoid them.
Can You Practice Medicine and Manage Your Practice?
Rosemarie Nelson,  May 9, 2012
Whether you practice alone, or in a group, if you're trying to see patients in this pay-for-volume environment and also run the business of your practice, you may be missing out on important opportunities.

PatientResources